Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182564 | 0.94 | CA12 (0.46) | CA1CA9CA12HSP90AA1HSP90AB1 | |
| SCHEMBL5292779 | 0.92 | ACHE (0.45) | CA1CA9CA12ACHECYP3A4 | |
| SCHEMBL4004898 | 0.88 | CYP3A4 (0.47) | CA1CA9CA12HSP90AA1HSP90AB1 | |
| SCHEMBL2329760 | 0.88 | ACHE (0.50) | CA1CA9CA12HSP90AA1HSP90AB1 | |
| SCHEMBL232409 | 0.88 | CA12 (0.45) | CA1CA9CA12HSP90AA1HSP90AB1 | |
| SCHEMBL9987262 | 0.87 | CA12 (0.42) | CA1CA9CA12HSP90AA1HSP90AB1 | |
| SCHEMBL11460575 | 0.86 | CA12 (0.44) | CA1CA9CA12HSP90AA1HSP90AB1 | |
| SCHEMBL3571948 | 0.86 | CA12 (0.44) | CA1CA9CA12HSP90AA1HSP90AB1 | |
| SCHEMBL22128469 | 0.86 | CA12 (0.44) | CA1CA9CA12HSP90AA1HSP90AB1 | |
| SCHEMBL356737 | 0.86 | CYP3A4 (0.52) | CA1CA9CA12HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110753558-B | Novel compounds and therapeutic uses thereof | 森陶里治疗有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11766483-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2023-09-26 | — | — | US | disclosed |
| EP-3606561-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| EP-3606558-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| US-11130730-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-09-28 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20200231538-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2020-07-23 | — | — | US | disclosed |
| US-20200147236-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2020-05-14 | — | — | US | disclosed |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2018-10-04 | — | — | US | disclosed |
| EP-1165495-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056702-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147236-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, CD47, STING1 | CA1 4755/4885CA9 4117/4885CA12 4003/4885 |
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | CA1 4372/4885CA9 3756/4885CA12 2887/4885 |
| US-11130730-B2 | Compounds and therapeutics uses thereof | MAVS, MYD88, CD47 | CA1 4733/4885CA9 3900/4885CA12 3828/4885 |
| US-11766483-B2 | Compounds and therapeutics uses thereof | MAVS, MYD88, CD47 | CA1 4733/4885CA9 3900/4885CA12 3828/4885 |
| US-20200231538-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, CD47, STING1 | CA1 4755/4885CA9 4117/4885CA12 4003/4885 |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CD47, MYD88, NFATC1 | CA1 4372/4885CA9 3756/4885CA12 2887/4885 |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | CA1 4372/4885CA9 3756/4885CA12 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.